360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Recombinant

Type: Keyphrase

Name: Recombinant

First reported 16 hours ago - Updated 3 hours ago - 1 reports

Phase II

Glycotope Has Completed Randomization of Phase ...

Glycotope GmbH / Glycotope Has Completed Randomization of Phase II Clinical Trial with Glycooptimized and Fully Human FSH-GEX(TM) for In Vitro Fertilization . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content ... [Published Best Invest - 16 hours ago]

Entities: Recombinant, Follicle Stimulating Hormone, Phase II

First reported 8 hours ago - Updated 8 hours ago - 1 reports

Vaxart’s Groundbreaking Tablet Influenza Vaccine Generates Protective Antibody Levels in Humans

SAN FRANCISCO--(BUSINESS WIRE)--Vaxart, a privately held company developing recombinant vaccines that are administered by tablet rather than injection, today announced positive safety and immunogenicity data from phase I clinical studies with its oral ... [Published Yahoo! Finance - 8 hours ago]

Entities: Vaccine, Influenza A H1N1 Virus, Antibody, Influenza

First reported 14 hours ago - Updated 14 hours ago - 1 reports

Medtronic Inc

News From The Annals Of Internal Medicine June 18 2013

1. Two Independent Reviews, Made Possible through Unprecedented Data Release, Raise Questions about rhBMP-2 rhBMP-2 provided little or no benefit compared to bone graft and may be associated with more harms, possibly including cancer Two independent reanalyses ... [Published Big News Network - 14 hours ago]

Entities: Internal Medicine, Recombinant, Medtronic Inc

First reported Jun 18 2013 - Updated Jun 18 2013 - 1 reports

Acambis PLC

Flu vaccine results bolster hopes for combating pandemic

A vaccine that could overcome the need for annual flu booster jabs has shown promising results in a Phase 1 clinical trial.Experts from Acambis plc say the vaccine could present a potential tool in the fight against a flu pandemic."We are very excited ... [Published Management in Practice - Jun 18 2013]

Entities: Influenza Vaccine, Pandemic, Acambis PLC, Vaccine, Influenza

First reported Jun 18 2013 - Updated Jun 18 2013 - 4 reports

Santarus Inc

Santarus And Pharming Announce FDA Acceptance For Review Of Ruconest

(Recombinant Human C1 Esterase Inhibitor) Biologics License Application SAN DIEGO & Leiden, The Netherlands (June 18, 2013) Santarus, Inc. (NASDAQ: SNTS) and... ... [Published Drugs.com - Jun 18 2013]

Entities: Santarus Inc, Ruconest, Pharming

First reported Jun 18 2013 - Updated Jun 18 2013 - 1 reports

Issue Summary June 18, 2013

issue, including articles on prostate cancer treatment, rivaroxaban in patients transitioned from vitamin K antagonist therapy, statin toxicity from clarithromycin or erythromycin, and recombinant human bone morphogenetic protein-2 in spinal fusion surgery, ... [Published Annals of Internal Medicine - Jun 18 2013]

Entities: clarithromycin, Spinal Fusion, Rivaroxaban, Naphthoquinone

First reported Jun 16 2013 - Updated Jun 16 2013 - 1 reports

Anti-Bacterial Activity of Recombinant Human β-Defensin-3 Secreted in the Milk of Transgenic Goats Produced by Somatic Cell Nuclear Transfer

by Jun Liu, Yan Luo, Hengtao Ge, Chengquan Han, Hui Zhang, Yongsheng Wang, Jianmin Su, Fusheng Quan, Mingqing Gao, Yong ZhangThe present study was conducted to determine whether recombinant human β-defensin-3 (rHBD3) in the milk of transgenic goats has ... [Published Elites TV - Jun 16 2013]

Entities: Transgenic, Recombinant, Escherichia Coli (E. Coli), Gland

First reported Jun 16 2013 - Updated Jun 16 2013 - 1 reports

Different Immunity Elicited by Recombinant H5N1 Hemagglutinin Proteins Containing Pauci-Mannose, High-Mannose, or Complex Type N-Glycans

by Shih-Chang Lin, Jia-Tsrong Jan, Ben Dionne, Michael Butler, Ming-Hsi Huang, Chung-Yi Wu, Chi-Huey Wong, Suh-Chin WuHighly pathogenic avian influenza H5N1 viruses can result in poultry and occasionally in human mortality. A safe and effective H5N1 vaccine ... [Published Elites TV - Jun 16 2013]

Entities: Proteins, Recombinant, Influenza A H5N1 Virus

First reported Jun 14 2013 - Updated Jun 14 2013 - 4 reports

PPTA Applauds Preserving Access to Orphan Drugs Acts PR Newswire

/PRNewswire/ -- The (PPTA) commends the Preserving Access to Orphan Drugs Acts, bipartisan legislation that makes an important policy clarification and will remove a barrier to research and development of rare disease therapies.Representative Jim Gerlach ... [Published Yahoo! Finance - Jun 14 2013]

Entities: Plasma Proteins, Orphan drug, Jim Gerlach, Drugs, Recombinant

First reported Jun 14 2013 - Updated Jun 14 2013 - 2 reports

Avastin Approved in Japan for Malignant Glioma

Anti-Cancer Agent “Avastin®," Obtained Approval for Additional Indication and Dosage and Administration of Malignant GliomaJune 14, 2013 (Tokyo) - Chugai Pharmaceutical Co., Ltd. [Main Office: Chuo-ku, Tokyo. Chairman & CEO: Osamu Nagayama (hereafter, ... [Published Pharma Live - Jun 14 2013]

Entities: Avastin, glioma, malignant

First reported Jun 14 2013 - Updated Jun 14 2013 - 1 reports

Pharmacokinetics Study of Recombinant Hirudin in the Plasma of Rats Using Chromogenic Substrate, ELISA, and Radioisotope Assays

by Su-yun Jiang, Jian Jiao, Ting-ting Zhang, Yong-ping XuAimTo compare the analytical methods used to study the pharmacokinetics of recombinant hirudin in the plasma of rats that had been injected with 125I-recombinant hirudin.Methods2.0 mg/kg 125I-recombinant ... [Published Elites TV - Jun 14 2013]

Entities: ELISA Enzyme-Linked Immunosorbent Assay, Recombinant, Pharmacokinetics, Substrate

First reported Jun 13 2013 - Updated Jun 13 2013 - 1 reports

CSL Behring doses first patient in Part 3 of Phase III hemophilia A study

CSL Behring, a plasma protein biotherapeutics company, has dosed the first patient in Part 3 of the company's AFFINITY clinical trial program, which is now in Phase III. AFFINITY is an open-label, non-randomized multi-center study evaluating the efficacy, ... [Published Individual.com - Jun 13 2013]

Entities: CSL Behring, Hemophilia A, Recombinant, Phase III

Quotes

"Completing randomization in this first large Phase II trial with a fully human glycosylated and glycooptimized GlycoExpress(TM) product is a major milestone for us and our investors. Based on the superior activity of FSH-GEX(TM) seen in the first trials with human volunteers, we are keen to see its performance in the randomized patient setting. FSH-GEX(TM) is the first of our glycooptimized, fully human non-antibody molecules validating our unique GlycoExpress(TM) platform and proving our commitment to deliver better therapies to patients in an efficient, cost effective manner" said Dr Steffen Goletz, CEO, CSO and Founder of Glycotope

Glycotope Has Completed Randomization of Phase ... [Published Best Invest - 16 hours ago]

...Alexandre Padilha, Brazil's Minister of Health. "Through this collaboration, we are able to strengthen our technological and industrial capabilities in the area of biologics manufacturing and improve the health of Brazilian citizens who are impacted by this rare disorder."

Protalix BioTherapeutics and Brazil's Ministry of Health Enter Into Supply and Technology Transfer [Published Nasdaq - 17 hours ago]

"I'm truly honored to accept this award and be recognized by Ernst & Young among the successful entrepreneurs in New Jersey," said Dr. Nader. "It's an exciting moment for the entire NPS team, which has achieved so much and works so hard each and every day to bring innovative therapeutics to patients suffering from rare diseases around the world."

NPS Pharmaceuticals' President and CEO Wins Ernst & Young Entrepreneur Of The Year 2013 Award [Published Individual.com - 17 hours ago]

...II studies we have planned for Pracinostat in the months ahead," said Daniel P Gold, Ph D , President and Chief Executive Officer of MEI Pharma. "We believe that Pracinostat truly has the potential to become a best-in-class drug. We intend to execute a comprehensive development program in order to realize its full potential and determine the most efficient registration path forward."

ACADIA Issues Multiple Presentations of Data from Trial of Pimavanserin; MEI Begins Phase II Tria ... [Published BioMedReports - 22 hours ago]

More Content

sort by: Date \| Relevance
Insmed Coverage Initiated at UBS AG (INSMD) [Published American Banking News - Stock Ratings - 35 mins ago]
Insmed Now Covered by Analysts at UBS AG (INSMD) [Published The Utah People's Post - 1 hour ago]
Protalix BioTherapeutics Rating Increased to Ou... [Published American Banking News - Stock Ratings - 4 hours ago]
Protalix BioTherapeutics Upgraded by Zacks to “... [Published The Utah People's Post - 4 hours ago]
June 14: Recent transplant news [Published American Society of Transplantation - 5 hours ago]
"Sets/Kits in Poland" Now Available at Fast Mar... [Published SBWire - 6 hours ago]
Total Access: YODA Gains Full Access to Clinica... [Published eyeforpharma.com - 7 hours ago]
Vaxart’s Groundbreaking Tablet Influenza Vaccin... [Published Yahoo! Finance - 8 hours ago]
OHSU analysis finds previous studies have overs... [Published News-Medical.Net - 9 hours ago]
The New Wave of Greek Yogurt [Published US News & World Report - 9 hours ago]
UBS AG Reiterates “Buy” Rating for Insmed Incor... [Published The Utah People's Post - 11 hours ago]
Protalix BioTherapeutics and Brazil’s Ministry ... [Published Pharma-Mag - 12 hours ago]
News From The Annals Of Internal Medicine June ... [Published Big News Network - 14 hours ago]
Medtronic bone graft has limited benefit, may c... [Published Borneo Bulletin - 16 hours ago]
Glycotope Has Completed Randomization of Phase ... [Published Best Invest - 16 hours ago]
Comparison of the effectiveness of antibody and... [Published 7thSpace - 17 hours ago]
Comprehensive Mapping Antigenic Epitopes of NS1... [Published Elites TV - 17 hours ago]
Protalix BioTherapeutics and Brazil's Ministry ... [Published Nasdaq - 17 hours ago]
NPS Pharmaceuticals' President and CEO Wins Ern... [Published Individual.com - 17 hours ago]
ACADIA Issues Multiple Presentations of Data fr... [Published BioMedReports - 22 hours ago]
Long lasting drug formulations [Published PharmCast - 23 hours ago]
Developmental Vaccine May Prevent TB Meningitis [Published RT Magazine - Jun 18 2013]
Medtronic Bone Graft Linked to Male Sterility, ... [Published QMED - Jun 18 2013]
A Novel Affinity Adsorbent For The Capture And ... [Published Bioresearch Online - Jun 18 2013]
Resistance, slaughter and pet vending top the a... [Published Farm Business - Jun 18 2013]
Flu vaccine results bolster hopes for combating... [Published Management in Practice - Jun 18 2013]
OHSU review: previous studies overstated eviden... [Published Brightsurf Science News - Jun 18 2013]
Santarus And Pharming Announce FDA Acceptance F... [Published Drugs.com - Jun 18 2013]
Santarus And Pharming Announce FDA Acceptance F... [Published Big News Network - Jun 18 2013]
Biodel Primed To Capitalize On Next Generation ... [Published Trefis - Jun 18 2013]

Blogs

sort by: Date \| Relevance
Protalix BioTherapeutics and Brazil’s Ministry ... [Published Pharma-Mag - 12 hours ago] Exclusive License and Supply Agreement With Pfizer Amended to Facilitate the Technology Transfer Protalix BioTherapeutics Inc. announced that it has entered into a supply and technology transfer agreement with Fundação Oswaldo Cruz (commonly referred ...
The Developing World’s Agricultural Biotech Pot... [Published Biotech Blog - Jun 17 2013] Copyright © thinkBiotech This guest post is from the BiotechBlog Intern, Fintan Burke . Fintan is a student at the School of Biotechnology at Dublin City University. Do you have a response to Fintan’s post? Respond in the comments section below. ...
Tianjin SinoBiotech & Beijing Bio-Fortune Annou... [Published Pharma-Mag - Jun 11 2013] Two FortuneRock (China) subsidiaries have granted a major global pharma firm US rights to develop their recombinant human serum albumin fusion protein drug IP for the treatment of human neutropenia. Tianjin SinoBiotech and Beijing Bio-Fortune, along ...
BARDA Awards Neumedicines $8.3M for Radiation S... [Published Pharma-Mag - Jun 10 2013] The US Department of Health and Human Services (DHSS) Biomedical Advanced Research & Development Agency (BARDA) awarded Neumedicines $8.3 million to fund further development of its recombinant interleukin-12 (IL-12) product HemaMax® (NMIL12-1), for treating ...
Scientific guideline: Guideline on quality of b... [Published Scientific guidelines: human and vet - Jun 10 2013] The principal aim of this guideline is to adapt some specific aspects of the quality guidance already in place for other recombinant production systems to the special case of transgenic animal systems. ...

Press Releases

sort by: Date \| Relevance
Santarus and Pharming announce FDA acceptance f... [Published Marketwire - Breaking News Releases - Jun 18 2013]
Santarus and Pharming announce FDA acceptance f... [Published PR inside - Jun 18 2013]
Santarus and Pharming Announce FDA Acceptance f... [Published Business Wire Health News - Jun 18 2013]
First-of-Its-Kind Independent Review of INFUSE®... [Published PR inside - Jun 17 2013]
Findings Presented at ENDO 2013 Support Therape... [Published Business Wire Health News - Jun 17 2013]